GLP-1 receptor agonists as a drug class have substantial clinical trial evidence supporting significant weight loss outcomes, with peer-reviewed research demonstrating statistically meaningful reductions in body weight in large randomized controlled trials
This property was demonstrated in studies by Sikiric et al
Abdominoplasty (Tummy Tuck) An abdominoplasty, or tummy tuck, addresses loose skin and separated abdominal muscles in the midsection after major weight loss
A 7.5 mg dose at this concentration means injecting 1.5 mL, which is at the upper limit of what most people find comfortable for a subcutaneous injection
The growing body of clinical evidence supporting the long-term efficacy and safety of agents such as semaglutide and tirzepatide has strengthened physician confidence and expanded reimbursement coverage in key markets Moreover, the rising interest from younger demographics, increased public awareness through social media, and celebrity endorsements are normalizing the use of obesity drugs, further accelerating consumer demand
